What are the limitations of the eln 2022 risk aml?

While the eln 2022 risk aml is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the eln 2022 risk aml to ensure safe bedside use and optimal diagnostic accuracy.

How does the eln 2022 risk aml compare to other Oncology scores?

The eln 2022 risk aml is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the eln 2022 risk aml free to use?

Yes. OpiCalc provides the eln 2022 risk aml completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

ELN 2022 Risk (AML)

Haematological Malignancies

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Calculated Interpretation

Intermediate Risk

Intermediate risk includes FLT3-ITD without adverse lesions and non-favorable/non-adverse profiles.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Interpretive Logic

Adverse lesions override favorable markers.
FLT3-ITD without adverse lesions now sits in intermediate risk regardless of allelic ratio.
Core binding factor, mutated NPM1, and bZIP CEBPA patterns remain favorable.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Favorable

Intermediate

Adverse

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

ELN 2022 Risk (AML) is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.

ELN 2022 Risk (AML)

Haematological Malignancies

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Calculated Interpretation

Intermediate Risk

Intermediate risk includes FLT3-ITD without adverse lesions and non-favorable/non-adverse profiles.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

CLINICAL INSIGHT

How it Works

Clinical Inputs

Core-binding factor fusion

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Adverse cytogenetics

KMT2A rearrangement

RUNX1 mutation

ASXL1 mutation

BCOR mutation

Interpretive Logic

Adverse lesions override favorable markers.
FLT3-ITD without adverse lesions now sits in intermediate risk regardless of allelic ratio.
Core binding factor, mutated NPM1, and bZIP CEBPA patterns remain favorable.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Favorable

Intermediate

Adverse

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Favorable, intermediate, or adverse AML risk assignment using ELN 2022 genetics.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

ELN 2022 Risk (AML) is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.